← Leaderboards
Herbert Hurwitz
Duke University
$2,172,341
Attributed
$2,172,341
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,172,341 · 4
By mechanism
M01$2,172,341 · 4
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Mark Wesley Dewhirst$12,821,035
- Darell D Bigner$25,397,506
- James L Abbruzzese$10,558,825
- Xiao-Fan Wang$23,927,835
- Kathryn I Pollak$19,822,874
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchClinical Trial Phase INeoplasm /Cancer ChemotherapyHuman Therapy EvaluationAntineoplasticsDrug Adverse EffectDrug Screening /EvaluationPharmacokineticsUracil AnalogFluorouracilCombination ChemotherapyCombination Cancer TherapyNeoplasm /Cancer Radiation TherapyPancreas NeoplasmsStomach NeoplasmsDosageOral AdministrationPiperidineNeoplasm /CancerDrug Administration Rate /DurationEnzyme InhibitorsBlood PressureNitric Oxide
Grant awards (18)
BIOMARKER AND CLINICAL EVALUATION OF BEVACIZUMAB (AVASTIN) TO DETERMINE THE ROLE$101,992
M01 · FY2005 · RR
Nitric Oxide in Anti-VEGF Therapy$15,223
M01 · FY2004 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2002 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2002 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2002 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$293,069
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$293,069
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$293,069
M01 · FY2001 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$117,022
M01 · FY2001 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$117,022
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2001 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$117,022
M01 · FY2001 · RR
BIOEQUIVALENCE COMBINATION 776C85/5FU PILL &INDIVIDUAL 776C85 &5FU PILL$40,907
M01 · FY2000 · RR
PH I: TWO WEEK PO ADMINISTRATION SCH 66336 ADVANCED CANCER$40,907
M01 · FY2000 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$40,907
M01 · FY2000 · RR
PH 1 XRT+5 FU+ENILURACIL--ADVANCED UNRESECTABLE UPPER GI MALIGNANCIES$0
M01 · FY2000 · RR